6533b862fe1ef96bd12c76b6

RESEARCH PRODUCT

Postoperative endophthalmitis incidence after intravitreal therapy: a comparison of two different preoperative antibiotic prophylaxis.

Sergio PiscitelloMaria Vadalà

subject

MaleVascular Endothelial Growth Factor Amedicine.medical_specialtyTriamcinolone acetonideAngiogenesis InhibitorsTriamcinolone AcetonideGroup BDexamethasone03 medical and health sciences0302 clinical medicineEndophthalmitisPostoperative ComplicationsAntibiotic prophylaxiPreoperative CaremedicineHumansEndophthalmitiAntibiotic prophylaxisGlucocorticoidsDexamethasoneAgedRetrospective StudiesAged 80 and overDrug ImplantsEndophthalmitisDose-Response Relationship DrugSettore MED/30 - Malattie Apparato Visivobusiness.industryIncidence (epidemiology)IncidenceIntravitreal therapyRetrospective cohort studyAntibiotic ProphylaxisMiddle Agedmedicine.diseaseSurgeryAnti-Bacterial AgentsOphthalmologyRegimenAnesthesiaIntravitreal Injections030221 ophthalmology & optometryFemalebusiness030217 neurology & neurosurgerymedicine.drug

description

Prevention of postoperative endophthalmitis (POE) is a goal of every ophthalmic procedure and also in intravitreal therapy (IVT). This comparative retrospective study targets whether systemic and topical preoperative antibiotic prophylaxis (PAP) regimen does prevent POE after IVT in a higher rate compared with topical PAP alone. Out of 6111 IVT performed over a period of 103.5 months, in the study group A patients were treated with systemic and topical PAP (2881 IVT), and in the study group B patients were treated only with topical PAP (3230 IVT). Intravitreal drugs were anti-VEGF, triamcinolone and dexamethasone implants. The incidence of POE in group A (1/2881 or 0.035 % per injection) was not significantly different (P = 0.4) from that in suite B (1/3230 or 0.031 % per injection). Our study states that systemic PAP does not modify the risk of postoperative endophthalmitis in patients treated with IVT.

10.1007/s10792-016-0307-3https://pubmed.ncbi.nlm.nih.gov/27586671